FDA Approval for Lurbinectedin
Lurbinectedin (brand name Zepzelca) is approved by the FDA for treating metastatic small cell lung cancer (SCLC) in adults who have progressed on or after platinum-based chemotherapy.[1]
How It Received Approval
The approval came in June 2020 under accelerated approval, based on tumor response rates and duration of response from the phase 2 basket trial (PM14-504). Full approval depends on confirmatory trials like the ongoing phase 3 ORRADIUS study.[1][2]
Specific Use in Small Cell Lung Cancer
It's indicated as monotherapy for relapsed SCLC after prior platinum therapy, typically in the second-line setting. Patients with disease progression within 6 months of finishing first-line platinum-based chemo (sensitive relapse) or later (refractory) both qualify.[1]
Approvals Outside the US
- EU (as Zepzelca): Approved in 2022 for the same SCLC indication after platinum failure.[3]
- Other regions: Similar approvals in Canada, Australia, and Brazil for relapsed SCLC; no broader indications yet.[3]
Ongoing Trials and Potential Expansions
Lurbinectedin is in trials for other cancers, including:
- Platinum-resistant ovarian cancer (phase 3 LUMINA trial).
- Advanced solid tumors like endometrial, head/neck, and mesothelioma (phase 2).
No additional approvals beyond SCLC as of now.[2]
Common Patient Questions
Patients often ask about eligibility: Requires ECOG performance status 0-2, adequate organ function, and no active brain metastases. It's given IV every 21 days at 3.2 mg/m².[1]
[1]: FDA Label for Zepzelca
[2]: ClinicalTrials.gov searches for lurbinectedin
[3]: EMA Approval Summary